Table 1.
Patient characteristics according to randomization arm
| Characteristic | Subcharacteristic | PHW mHealth+ Arm | PHW mHealth− Arm |
|---|---|---|---|
| No clusters | 4 | 6 | |
| No subjects total | 446 | 524 | |
| No subjects per cluster, mean (range) | 112 (74–163) | 87 (47–132) | |
| Female, n (%) | 299 (67) | 339 (65) | |
| Age, median (range), years | 34 (15–67) | 36 (16–76) | |
| CD4 cell count at ART initiation, median (IQR), cells/μl | 156 (72–216) | 167 (81–219) | |
| Plasma HIV-1 RNA at ART initiation, geometric mean, copies/ml | 44,833 | 44,083 | |
| Plasma HIV-1 RNA at ART initiation, mean (SD), log10 copies/ml | 4.65 (0.99) | 4.64 (0.87) | |
| Baseline viral load > 100,000 copies/ml, n (%) | 203 (46) | 218 (42) | |
| Baseline WHO stage, n (%) | |||
| 1 | 132 (30) | 155 (30) | |
| 2 | 165 (37) | 184 (35) | |
| 3 | 94 (21) | 130 (25) | |
| 4 | 54 (12) | 55 (10) | |
| Baseline ARV regimen, n (%) | |||
| Combivir/Efavirenz | 121 (27) | 155 (30) | |
| Combivir/Nevirapine | 162 (36) | 191 (36) | |
| Stavudine/Lamivudine/Efavirenz | 44 (9.9) | 51 (9.7) | |
| Stavudine/Lamivudine/Nevirapine | 115 (26) | 124 (24) | |
| Other | 4 (0.9) | 3 (1) | |
| Clinic distance to central clinic, mean (range), km | 18.4 (7.7–32.5) | 28.3 (12.9–40.5) | |
| Subjects on ART prior to start of trial, n (%) | 165 (37) | 165 (31) | |
| Subject pre-trial subject duration on ART, median (range), weeks | 44.3 (1.0–89.1) | 37.7 (1.1–89.4) | |
| Pre-trial 24 week virologic failures, n/N (%) | 45/93 (48.4) | 40/98 (40.8) | |
| Pre-trial 48 week virologic failures, n/N (%) | 16/66 (24.2) | 20/62 (32.3) | |
PHW Peer health worker, IQR Interquartile range, SD Standard deviation